Latest Breaking News On - Global portfolio division at takeda - Page 1 : comparemela.com

EC authorises the first UL97 protein kinase inhibitor (livtencityTM) for adults with post-transplant refractory cytomegalovirus infection.

Northern irelandUnited kingdomRamona sequeiraLuciano potenaEuropean commissionEuropean society for organ transplantationGlobal portfolio division at takedaGlobal portfolio divisionEuropean societyOrgan transplantation